

EPHRAIM LANSKY CURRICULUM VITAE 13 Jun 2019

Email: punisyn@gmail.com, Telephone: +972 77 300 1612



M.D. University of Pennsylvania School of Medicine, 1982
Ph.D. Leiden University 2008 (Pharmacognosy, The Netherlands)
M.B.A. University of Bradford 2008 (UK)
B.A. New College 1975 (Psychology / Biology, Sarasota, Florida, USA)

Doctoral thesis (Leiden University): Anticancer pharmacognosy of *Punica granatum*

Master's thesis (University of Bradford): Strategic management of chaos

Baccalaureate thesis (New College): Consciousness and the ergotropic and trophotropic systems of arousal

PRESENT EMPLOYMENT

Series Editor. CRC Press, 1. Medicinal and Aromatic Plants: Industrial Profiles
2. Traditional Herbal Medicines for Modern Times

CEO, CTO, Rimonext Ltd. (2019), Haifa, Israel

Research Fellow, Institute of Evolution, University of Haifa, Haifa, Israel

BOOKS (as lead author)

2017, *Harmal: The Genus Peganum* CRC Press
2014, *Caper: The Genus Capparis* CRC Press
2010, *Figs: The Genus Ficus* CRC Press
2007, *Pomegranate: The Most Medicinal Fruit*, Basic Books

PEER REVIEWED PUBLICATIONS (as sole author or co-author)

Putative sonosensitizer from seeds of *Peganum harmala*. *Ann Pharmacol Pharm* 2017; 2(24): 1123.

High environmental stress yields greater tocotrienol content while changing vitamin e profiles of wild emmer wheat seeds. *J Med Food*. 2015; 18(2):216-23.

Increases in both acute and chronic temperature potentiate tocotrienol concentrations in wild barley at 'Evolution Canyon'. *Chem Biodivers*. 2013; 10(9):1696-705.

Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clin Gastroenterol Hepatol*. 2013; 11(10):1276-1280.

Anticancer potential of aloes: antioxidant, antiproliferative, and immunostimulatory attributes. *Planta Med.* 2012; 78(9):843-52.

Anticancer attributes of desert plants: a review. *Anticancer Drugs.* 2012; 23(3):255-71.

'Tocol-omic' diversity in wild barley, short communication. *Chem Biodivers.* 2011; 8(12):2322-30.

Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. *Carcinogenesis* 2011; 32(6):888-96.

Pomegranate (*Punica granatum*) seed linolenic acid isomers: concentration-dependent modulation of estrogen receptor activity. *Endocr Res* 2010; 35(1):1-16.

Pomegranate fruit extract impairs invasion and motility in human breast cancer. *Integr Cancer Ther* 2009; 8(3):242-53.

Ficus spp. (fig): ethnobotany and potential as anticancer and anti-inflammatory agents. *J Ethnopharmacol* 2008; 119(2):195-213.

Punica granatum: heuristic treatment for diabetes mellitus. *J Med Food.* 2007; 10(2):213-7.

Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J Ethnopharmacol* 2007; 109(2):177-206

Transcendental meditation: a double-edged sword in epilepsy? *Epilepsy Behav* 2006; 9(3):394-400.

Meditation and epilepsy: a still hung jury. *Med Hypotheses* 2006; 67(2):247-50.

Beware of pomegranates bearing 40% ellagic acid. *J Med Food* 2006; 9(1):119-22.

Pomegranate as a cosmeceutical source: pomegranate fractions promote proliferation and procollagen synthesis and inhibit matrix metalloproteinase-1 production in human skin cells. *J Ethnopharmacol.* 2006; 103(3):311-8.

Complex and simple. *Leuk Res* 2005; 29(6):601-2.

Pomegranate (*Punica granatum*) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel. *Invest New Drugs* 2005; 23(2):121-2. Erratum in: *Invest New Drugs.* 2005; 23(4):379.

Possible synergistic prostate cancer suppression by anatomically discrete pomegranate fractions. *Invest New Drugs.* 2005; 23(1):11-20.

Breast cancer chemopreventive properties of pomegranate (*Punica granatum*) fruit extracts in a mouse mammary organ culture. *Eur J Cancer Prev* 2004; 13(4):345-8.

Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. *J Med Food* 2004; 7(3):274-83.

Differentiation-promoting activity of pomegranate (*Punica granatum*) fruit extracts in HL-60 human promyelocytic leukemia cells. *J Med Food* 2004; 7(1):13-8.

Rapid dereplication of estrogenic compounds in pomegranate (*Punica granatum*) using on-line biochemical detection coupled to mass spectrometry. *Phytochemistry* 2004; 65(2): 233-41.

Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. *J Med Food*. 2003; 6(3):157-61.

Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. *Angiogenesis* 2003; 6(2):121-8.

Chemopreventive and adjuvant therapeutic potential of pomegranate (*Punica granatum*) for human breast cancer. *Breast Cancer Res Treat* 2002; 71(3):203-17

Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. *J Ethnopharmacol* 1999; 66(1):11-7.

Possibility of hypnosis as an aid in cancer therapy. *Perspect Biol Med* 1982, 25(3):496-503.

Some kinetic and inhibition properties of human brain mitochondrial monoamine oxidase (EC 1.4.3.4). *Neurobiology*. 1974; 4(3):180-90.

PATENTS (as sole inventor)

Phytoestrogen supplement prepared from pomegranate seeds and a herbal mixture or coconut milk. US Patent, 5,891,440, 1999.

Pomegranate supplements prepared from pomegranate material including pomegranate seeds. US Patent, 6,060,063, 2000.

Pomegranate juice and oil products. South Africa Patent, 2002/3898, 2003.

Pomegranate juice and oil products. Australia Patent, 774619, 2004.

Phytoestrogen supplements. Israel Patent, 149521, 2004.

LICENSES

1. Hypnosis, Israel, active
2. Medicine
 - a. Pennsylvania, New York, Iowa, New Jersey, Massachusetts (inactive)
 - b. Israel (active)

CONFERENCE PRESENTATIONS (as sole author or co-author)

The lympho-neuric syncytium: a new model for the integrated use of ayahuasca on mind and body. Invited Address, World Ayahuasca Conference, ICEERS, 2019, Girona, Spain, 31 May - 2 June.

Phyto-photo-biomodulation for PTSD etc., Conference on Trauma and Mental Health 2017, Jerusalem, Israel, 21-23 May.

Punica granatum and inflammation-induced cancer. Inflammation-Induced Cancer Conference, Jerusalem, Israel, 24-27 March 2012.

Prescription-only, cancer preventive and therapeutic pomegranate nutraceuticals. Invited Address, Fourth International Conference on Mechanism of Action of Nutraceuticals. (ICMAN4), Tel Aviv, Israel, October 21-22, 2007.

The secret to a w-i-d-e therapeutic index. Invited Address, 3rd Haifa Cancer Prevention Workshop, Haifa, Israel, October 15-17, 2007.

Development of a pomegranate product for breast cancer prevention. American Society of Pharmacognosy 48th Annual Meeting, Portland, Maine, USA, July 14-18, 2007

Prevention of mammary tumorigenesis by aqueous and lipid pomegranate fruit extracts: in vitro and in vivo studies. 98th Annual Meeting of American Association of Cancer Research, Los Angeles, 14-18 April, 2007.

Pomegranate-prostate "intercrinology": novel anticancer drug opportunities. 2nd Joint American Israel Conference on Cancer, Jerusalem, 28-30 June, 2006.

Transcendental Meditation® (TM®): "Two-edged sword" in the etiology and management of epilepsy. Clinical Neurology and Neurophysiology, Tel Aviv, Israel, March 6-8, 2006.

Punicic acid: a putative chemopreventive agent. International Cancer Prevention Conference, Dead Sea, Israel, May 6-8, 2004.

Therapeutic synergy in pomegranate. 94th Annual Meeting of American Association for Cancer Research, Washington, DC, 11-14 July 2003.

Chemopreventive effects of pomegranate extracts in a mouse mammary organ culture (MMOC). 13th Annual Meeting of the North American Menopause Society, Chicago, Illinois, USA, October 3-5, 2002.

Chemopreventive and therapeutic complementarity of Rimonest™ pomegranate (*Punica granatum*) fruit extracts on gene targets in human prostate cancer cells. First International Symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, The Netherlands, September 23-25, 2002.

Antimutagenic potential of pomegranate (*Punica granatum*). 8th International Conference on Environmental Mutagens, Shizuoka, Japan, October 21-26, 2001.

Chemopreventive strategy in pomegranate (*Punica granatum*): implications for evolution and treatment. Invited Lecture, International Symposium on Dietary and Medicinal Antimutagens and Anticarcinogens: Molecular Mechanism and Chemopreventive Potential, Seoul, Korea, October 17-19, 2001.

Further studies on pomegranate and breast cancer: apoptosis and differential toxicity to normal breast epithelial cells. IV Madrid Breast Cancer Conference, Madrid, Spain June 7-9, 2001.

Effect of pomegranate extracts on proliferation of human prostatic epithelial and stromal cells in vitro. Annual Meeting of Nordic Association for Andrology (NAFA), Malmo, Sweden, September 2, 2000.

Pharmacological and therapeutic properties of pomegranate. First International Conference on The Pomegranate, Orihuela, Spain, 1998.

Addiction, well-being, and cure: a homeostatic model. 2nd Annual Dead Sea Conference on The Anatomy of Well-Being. Tiberias, Israel, 28 November-2 December, 1993.

Heuristic pharmacognosics in King Solomon's garden. Presented at International Symposium on Medicinal and Aromatic Plants, March 22-25, 1993. Printed in *Acta Horticulturae*, 344: 166-177, 1993.

Qigong as a putative treatment for immuno-deficiency syndromes. First World Conference for Academic Exchange of Medical Qigong, Beijing, China, 1988.

Acupuncture and hypnosis as synergistic therapies. American Society of Clinical Hypnosis, Annual Scientific Meeting, San Francisco, 1984.

PREVIOUS EMPLOYMENT

1982-1983 Intern in Psychiatry, Pennsylvania Hospital, Philadelphia, Pennsylvania, USA

1983-1988 Private Practice, Philadelphia, Pennsylvania, USA

1989-1992 Private Practice, Iowa City and Waterloo, Iowa, USA

1991 Emergency Physician, Native American Hospital, Owyhee, Nevada, USA

1991-1993 Emergency Physician, Mercy Hospital, Corning, Iowa, USA

1992-1993 Emergency Physician, Nantucket General Hospital, Nantucket, Massachusetts, USA

1993- present Private Practice, Haifa, Israel

1997-1999 Physician-Homeopath, Kupot Cholim Meuhedet, Ramat HaSharon and Haifa, Israel

1997-1999 Physician-Homeopath, Kupot Cholim Maccabi, Herzlia and Bnai Brak, Israel

1999- 2018 Co-Founder, CEO and Scientific Director, Rimonest Ltd., Haifa, Israel

2006-2018 Scientific Director, Punisyn Pharmaceuticals, Haifa, Israel

Resident Psychiatrist, 2011, Jerusalem Mental Health Center, Jerusalem
2019-present, CEO, CTO, Rimonext Ltd., Haifa, Israel

OTHER

2nd degree black belt (*nidan*), Kokikai Aikido, Chief Instructor, Israel.

Member, Israel Association for Classical Homeopathy

Member, American Institute of Homeopathy

Member, American Society of Clinical Hypnosis

Member, American Telemedical Association